Japanese firm builds on existing alliance to gain most global rights to US company’s potential best-in-class drug for lymphoma and B-cell malignancies.
Japan’s Kyowa Kirin Co. Ltd. has acquired rights in most global markets to MEI Pharma Inc.’s phosphatidylinositol 3-kinase (PI3K) delta inhibitor ME-401, a promising oral, once-daily candidate moving through clinical development in follicular lymphoma and B-cell malignancies.
The major deal builds on and expands a November 2018 license agreement between the firms for the molecule in the Japan market and will immediately give MEI $100m upfront in cash as well as an
A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.
GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
